LFA
TOVX icon

Landmark Financial Advisors’s Theriva Biologics TOVX Stock Holding History

Landmark Financial Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-92
Closed -$5K – 81
2022
Q2 		$5K Sell
92
-5
-5% -$286 ﹤0.01% 80
2022
Q1 		$6K Hold
97
– – ﹤0.01% 84
2021
Q4 		$7K Buy
+97
New +$9.15K ﹤0.01% 85

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Landmark Financial Advisors's TOVX Position: Q3 2022 in Review

Landmark Financial Advisors sold out of Theriva Biologics (TOVX) in Q3 2022, closing a stake of 92 shares — an estimated $5K sold.

Landmark Financial Advisors first reported a position in TOVX in Q4 2021 and held it in 3 quarters. The position peaked at $7K in Q4 2021. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

  • Landmark Financial Advisors reported no remaining Theriva Biologics position as of Q3 2022 after selling out during the quarter.
  • Landmark Financial Advisors sold 92 Theriva Biologics shares in Q3 2022, an estimated $5K.
  • Landmark Financial Advisors first reported a position in Theriva Biologics in Q4 2021 and held it in 3 quarters.
  • Landmark Financial Advisors's Theriva Biologics position peaked at $7K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on Landmark Financial Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.